文献速递脊柱关节炎

OMERACT Filter 2.1 在银屑病关节炎中筛选身体功能域工具:HAQ-DI 与 SF-36 PF 获临时认可

OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF.
PubMed 文献 · Semin Arthritis Rheum · 2021-07-24

本研究按 OMERACT Filter 2.1 流程,评估 HAQ-DI 与 SF-36 PF 两个工具在银屑病关节炎(PsA)试验中测量身体功能的表现。工作组通过两项系统文献综述及补充证据评价七项测量属性,并经 OMERACT 技术咨询组(TAG)与 GRAPPA 社区评议,对两个工具均给出「临时认可」。

要点

  • HAQ-DI 与 SF-36 PF 均获 OMERACT Filter 2.1 临时认可,可用于 PsA 试验身体功能测量。
  • 证据覆盖领域匹配、可行性及七项测量属性,以 SOMP 表呈现。
  • GRAPPA 两轮 Delphi 中 HAQ-DI 认可票为 93.9% 与 97.5%,SF-36 PF 为 86.7% 与 77.3%。

核心结论

  • HAQ-DI 与 SF-36 PF 均按 OMERACT Filter 2.1 获得临时认可,用于银屑病关节炎试验中身体功能域的测量。

研究设计与样本

  • 遵循 OMERACT Filter 2.1 指南,成立工作组评估领域匹配与可行性。
  • 开展两项系统文献综述,识别支持两工具测量属性的相关文献。
  • 评价七项测量属性,并补充新证据填补空白,结果提交 OMERACT TAG 与 GRAPPA 社区认可。

主要发现

  • HAQ-DI 与 SF-36 PF 的七项测量属性结果以测量属性汇总(SOMP)表呈现。
  • 工作组对两个工具均提出「临时认可」,证据体系获 OMERACT TAG 批准。
  • GRAPPA 成员两轮 Delphi 中,HAQ-DI 获 93.9% 与 97.5% 认可票,SF-36 PF 获 86.7% 与 77.3%。

关键数值与推荐

  • 临时认可适用于 PsA 试验中身体功能域的测量,工具为 HAQ-DI 与 SF-36 PF。
  • GRAPPA Delphi 认可票:HAQ-DI 93.9% 与 97.5%;SF-36 PF 86.7% 与 77.3%。

临床怎么用

  • 在 PsA 临床试验中选择身体功能测量工具时,可考虑使用获临时认可的 HAQ-DI 或 SF-36 PF。
  • 「临时认可」提示证据尚待完善,使用者应关注后续 OMERACT 更新与正式认可进展。

局限性

  • 原文摘要未报告两项系统文献综述的检索范围、纳入研究数量及合并数值。
  • 临时认可基于现有证据与 Delphi 投票,摘要未说明各测量属性具体数值与不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Physical function is one of the core domains to be measured in all trials in psoriatic arthritis (PsA). We aimed to evaluate two instruments for physical function in PsA: The Health Assessment Questionnaire-disability index (HAQ-DI) and the physical functioning subscale of the Medical Outcome Survey Short-Form 36 items (SF-36 PF). METHODS: We followed guidelines set out by the OMERACT Filter 2.1. A working group was formed to evaluate each instrument for domain match and feasibility to reach consensus. Two systematic literature reviews (SLRs) were conducted to identify the relevant articles supporting measurement properties of both instruments. Five additional measurement properties were appraised: construct validity, test-retest reliability, longitudinal construct validity, clinical trial discrimination, and threshold of meaning. New evidence was synthesized to fill the gap. Data were presented to the OMERACT technical advisory group (TAG) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) community for endorsement. RESULTS: The results for seven measurement properties for HAQ-DI and SF-36 PF were presented in Summary of Measurement Property (SOMP) tables. The working group proposed "Provisional Endorsement" for both instruments. The body of evidence was approved by the OMERACT TAG. In two Delphi exercises among GRAPPA members, HAQ-DI received 93.9% and 97.5% endorsement votes, while that for SF-36 PF were 86.7% and 77.3%. CONCLUSION: Both HAQ-DI and SF-36 PF were provisionally endorsed for the measurement of physical function in PsA trials, using the OMERACT Filter 2.1.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Leung YY, Orbai AM, Hojgaard P, et al. OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. Semin Arthritis Rheum. 2021. PMID: 34392975. doi:10.1016/j.semarthrit.2021.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。